ONCS Stock News Oncosec Medical Inc (ONCS) 0.4950 07/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncosec Medical Inc (ONCS) 0.4950 $ONCS

OncoSec Medical To Present at 2014 DNA Vaccine Conference
Business Wire - Thu Jul 17, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that several company representatives will present at the International Society of DNA Vaccines (ISDV) 2014 DNA Vaccine Conference, being held July 21-23, 2014 at the Westin San Diego Gaslamp Quarter Hotel in San Diego, CA.

OncoSec Medical To Present at Bioelectrochemistry Gordon Research Conference on July 8 and July 10
Business Wire - Wed Jul 02, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announces that Robert Pierce, M.D., Chief Medical Officer, and Richard Heller, Ph.D., Scientific Advisory Board member, will present at the Bioelectrochemistry Gordon Research Conference being held July 6-11, 2014 at the University of New England in Biddeford, ME.

OncoSec Medical Appoints Dr. Soldano Ferrone to Scientific Advisory Board
Business Wire - Wed Jun 25, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, has appointed Dr. Soldano Ferrone, M.D., Ph.D., to the company's Scientific Advisory Board. Dr. Ferrone is an internationally renowned expert in tumor immunology, and will contribute his considerable expertise to the company as it works to advance an expanding intratumoral immunotherapy pipeline.

OncoSec Medical Announces YTD Results as of April 30, 2014
Business Wire - Fri Jun 13, 8:00AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced financial results for the nine months ended April 30, 2014.

OncoSec Medical Issues Annual Letter To Shareholders
Business Wire - Thu Jun 12, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, today issued the following letter from Punit Dhillon, President and CEO, to the company's shareholders:

Top Five OTC Sector Trading List: OncoSec Medical Incorporated, Liquefield Natural Gas Ltd, Green and Hill Industries, Inc. Eco Building Products, Inc. IntelGenx Technologies Corp.
PR Newswire Europe - Wed Jun 11, 7:02AM CDT
LONDON, June 5, 2014 /PRNewswire/ --

OncoSec Medical raises USD16m from offering of shares & warrants
M2 - Tue Jun 10, 7:49AM CDT
Biopharmaceutical company OncoSec Medical (OTCQB:ONCS) reported on Tuesday the completion of its direct offering of 22,535,212 shares of its common stock at a price of USD0.71 per share.

OncoSec Medical Closes $16 Million Registered Direct Offering
Business Wire - Tue Jun 10, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced today that it has closed a registered direct offering of 22,535,212 shares of its common stock at a price of $0.71 per share and warrants to purchase up to an aggregate of 7,887,325 shares of common stock at an exercise price of $0.90 per share for a term of five years. The offering closed on June 6, 2014.

OncoSec Medical expects USD16m from direct offering of securities
M2 - Thu Jun 05, 5:18AM CDT
Cancer immunotherapy company OncoSec Medical (OTCQB:ONCS) said on Wednesday that it plans to issue USD16m of securities in a registered direct offering.

OncoSec Medical Announces $16 Million Registered Direct Offering
Business Wire - Wed Jun 04, 8:04AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced today that it has entered into definitive agreements with institutional investors to purchase approximately $16 million of securities in a registered direct offering. OncoSec has agreed to sell to such investors an aggregate of 22,535,212 shares of its common stock at a price of $0.71 per share. Additionally, investors will receive warrants to purchase up to an aggregate of 7,887,325 shares of common stock at an exercise price of $0.90 per share for a term of five years.

OncoSec Medical to Present at LD Micro 4th Invitational
Business Wire - Tue Jun 03, 5:02AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, will present at the LD Micro 4th Invitational, taking place Wednesday, June 4, 2014 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. This presentation will be the first of its kind to include new positive interim data from the company's Phase 2 melanoma study, which was recently exhibited at the 2014 ASCO Annual Meeting.

OncoSec Medical Presents Positive Phase 2 Interim Data Evaluating ImmunoPulse in Melanoma
Business Wire - Mon Jun 02, 8:31AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced interim data from its Phase 2 melanoma study at the American Society of Clinical Oncology's (ASCO) 50th Annual Meeting in Chicago. The abstract, titled "Systemic anti-tumor effect and clinical response in a Phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma" (ASCO Abstract #9025), was presented by Adil Daud, M.D., OncoSec's Chief Clinical Strategist and Principal Investigator of the Phase 2 melanoma study, and selected for discussion during a poster highlights session for melanoma/skin cancers led by Axel Hauschild, M.D., Ph.D.

OncoSec Medical To Present at Four Events in June
Business Wire - Tue May 27, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at four events in June. The company's agenda includes a number of high-profile scientific and investment conferences, coming on the heels of their presentation of new clinical data at the 2014 ASCO Annual Meeting. OncoSec's June meeting itinerary is as follows:

GACR Sees Share Volume Surge After Release Of First Quarter Financial Results
ACCESSWIRE - Fri May 23, 8:24AM CDT
Green Automotive Company Corp. (OTCQB: GACR) saw its share volume skyrocket on May 22nd with 13,436,426 shares exchanging hands, nearly four times higher than its three month daily average volume of 3,609,991 shares.

OncoSec Medical Inc. To Be Featured Presenter At 3rd Annual Marcum MicroCap Conference
ACCESSWIRE - Fri May 16, 7:58AM CDT
OncoSec Medical Incorporated (OTCQB: ONCS) saw its share volume slightly drop on May 15th with 2,589,613 shares exchanging hands, relatively lower than its three month daily average volume of 3,420,852 shares.

OncoSec Medical to Present at Two Conferences in New York City in April
Business Wire - Mon Mar 31, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will present at the 13th Annual Needham Healthcare Conference and the HemOnc Today Melanoma and Cutaneous Malignancies Meeting in April.

PUNIT DHILLON of OncoSec Medical Incorporated (ONCS)-Other O bought Shares of ONCS
M2 - Fri Mar 21, 7:39AM CDT
Reported by InsiderCow.com at 2014-03-20 14:21:26 ET

OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Mon Mar 17, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).

OncoSec Medical to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial
Business Wire - Wed Mar 12, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 97

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 51

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 88

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

DexCom Faces Class Action Lawsuit Over Securities Fraud Claims

Updated Category News Views 104

Overview of the Class Action Against DexCom, Inc. Investors in DexCom, Inc. are currently navigating important developments as a class action lawsuit has been filed. This legal action involves serious allegations of securities fraud against the company. Shareholders who have purchased DexCom securities may be affected, raising important questions about financial integrity...

Continue Reading
Amaroq Minerals Announces AGM Results and Future Directions

Updated Category News Views 209

Amaroq Minerals Ltd. Annual General Meeting Results Amaroq Minerals Ltd. is proud to share the results from its recent Annual General Meeting (AGM), reflecting a robust commitment from shareholders in shaping the future direction of the company. Held in a welcoming atmosphere, the event focused on critical decisions that underscore the corporation's strategic objectives...

Continue Reading
Explore the Theme of Connection and Creation at CIFF 2026

Updated Category News Views 254

Exciting New Developments at CIFF 2026 CIFF, the China International Furniture Fair, is gearing up for its 57th edition in March 2026. With a fresh theme, "CONNECT • CREATE", the event reflects the dynamic landscape of the furniture industry. The fair will facilitate exceptional connections within the furniture supply chain, including production, distribution, and...

Continue Reading
SpaceX's Starship to Showcase Advanced Starlink Technologies

Updated Category News Views 545

SpaceX's Latest Milestone in Satellite Technology Elon Musk's company, SpaceX, is gearing up for an exciting upcoming test flight of its Starship launch vehicle. The mission's highlight is the planned deployment of 10 model Starlink satellites, marking a significant step in demonstrating SpaceX's prowess in the satellite launch industry. The Innovative Starlink Satellites...

Continue Reading
DATAMYTE Introduces AI Efficiency in Mobile Inspections for APQP

Updated Category News Views 354

Transforming Quality Inspections with AI at DATAMYTE DATAMYTE, a leader in manufacturing technology, is truly reshaping the way inspections are conducted in the industry. By utilizing its innovative DIGITAL CLIPBOARD mobile platform alongside the powerful DATAMYTE GPT Artificial Intelligence System, the company is redefining the manual processes traditionally associated...

Continue Reading